Bone Pins Market by Product Type (Smooth Pin, Threaded Pin), Material (Biodegradable, Stainless Steel, Titanium), Application, End User, Sales Channel - Global Forecast 2025-2032
Description
The Bone Pins Market was valued at USD 176.89 million in 2024 and is projected to grow to USD 187.40 million in 2025, with a CAGR of 6.44%, reaching USD 291.57 million by 2032.
An authoritative introduction framing clinical needs, regulatory expectations, material innovation and supply dynamics that shape contemporary bone pin deployment
The contemporary bone pin landscape sits at the intersection of surgical necessity, materials science, and evolving care models. Clinicians consistently seek implants that deliver predictable fixation while minimizing complications, and this demand has driven a nuanced expansion of available materials and product designs. Meanwhile, regulatory and reimbursement pressures incentivize manufacturers to demonstrate clinical differentiation through comparative outcomes, device safety improvements, and clear value propositions for providers and payers. As a result, stakeholders across the value chain are recalibrating priorities to emphasize biocompatibility, ease of use in the operating theater, and downstream patient recovery metrics.
Transitioning from traditional stainless steel options to novel biodegradable constructs reflects a broader shift toward implants that mitigate long-term hardware complications and secondary procedures. Concurrently, the refinement of threaded and smooth pin formats has focused on surgical ergonomics and fixation predictability across anatomical sites. Supply chain resilience and manufacturing scalability remain focal points as providers demand consistent quality and timely availability. Taken together, these forces create a dynamic environment where clinical evidence, materials innovation, regulatory clarity, and commercial execution converge to define competitive advantage for industry participants.
How evolving clinical priorities, regulatory refinement, supply chain pressures and material breakthroughs are collectively redefining strategic priorities across the bone pin sector
The bone pin sector is undergoing transformative shifts prompted by changes in clinical practice, material engineering, and care delivery pathways. Surgeons are increasingly selective in implant choice, favoring devices that reduce secondary interventions and improve rehabilitation timelines. This clinical preference has elevated interest in biodegradable options and high-performance alloys, prompting manufacturers to accelerate development and to curate evidence that speaks directly to operative efficiency and patient-centric outcomes. In parallel, digital health technologies and improved imaging capabilities are refining preoperative planning and implant selection, enabling more precise fixation strategies and tailored device selection for complex anatomies.
Regulatory evolution is another critical vector of change. Authorities are refining guidance around post-market surveillance and comparative clinical assessment, which in turn raises the bar for demonstrating safety and long-term performance. Payors and hospital purchasing groups are responding by prioritizing devices that demonstrate total cost of care improvements rather than simple unit price reductions. Supply chain pressures and raw material availability have created incentives for regional manufacturing and strategic inventory management. Altogether, these shifts compel manufacturers to adopt integrated product development plans that align material science innovations, clinical evidence generation, and robust commercialization frameworks to remain competitive in a rapidly advancing clinical landscape.
Strategic responses to tariff-induced supply pressures that drive sourcing diversification, nearshoring considerations and procurement frameworks to protect surgical continuity
Tariff policy and trade measures can materially influence sourcing decisions, manufacturing footprints, and procurement strategies across the medical device ecosystem. Recent changes to United States tariff structures have reverberated through supply chains, prompting some manufacturers to reassess overseas production models and to explore nearshoring or dual-sourcing approaches. This recalibration affects not only raw material procurement but also the costs and logistics associated with finished device distribution. Hospitals and purchasing departments are consequently adjusting contract terms and inventory policies to mitigate potential disruptions and price variability.
In response, many organizations are increasing transparency across supplier relationships and investing in scenario planning to preserve surgical continuity. Device developers are evaluating potential redesigns that optimize material utilization and reduce dependency on tariff-exposed components. At the same time, procurement groups are enhancing their evaluation frameworks to consider total delivered cost, lead time certainty, and supplier risk profiles rather than focusing on per-unit list prices alone. These practices create a more resilient commercial environment but also require closer collaboration between clinical, regulatory, and supply chain teams to maintain device availability for critical procedures.
Key segmentation insights that illuminate how material science, device architecture, clinical application, end user dynamics and sales channels shape product differentiation
A nuanced understanding of segmentation is essential to navigate product development and commercialization for bone pins. Based on material, product portfolios include biodegradable options as well as traditional stainless steel and titanium constructs; the biodegradable category itself is differentiated into metal and polymer variants, where metal biodegradable pins commonly leverage magnesium alloys and polymer biodegradable pins utilize chemistries such as polyglycolic acid and polylactic acid. Each material pathway presents distinct clinical trade-offs in terms of degradation profiles, fixation strength, and imaging compatibility, and these characteristics influence surgeon preference and device positioning within treatment algorithms.
Based on product type, offerings typically distinguish between smooth pins and threaded pins, with each geometry delivering specific insertion dynamics and holding characteristics relevant to clinical scenarios. Based on application, bone pins are deployed across dental surgery, external fixation, internal fixation, and spinal surgery contexts, requiring tailored design considerations for anatomical constraints and biomechanical loads. Based on end user, adoption patterns differ among ambulatory centers, hospitals, orthopedic clinics, and specialty centers, with hospitals further segmented into private and public providers that operate under divergent procurement and budgetary regimes. Based on sales channel, distribution is achieved through direct sales, distributors, hospital purchasing departments, and online channels, and each route to market demands distinct commercial capabilities and support models. Integrating these segmentation layers enables more precise targeting of clinical evidence generation, pricing strategies, and post-market support to satisfy diverse stakeholder needs.
Comparative regional insights highlighting how procurement norms, regulatory environments and clinical adoption patterns vary across the Americas, Europe Middle East & Africa and Asia-Pacific
Regional dynamics exert a strong influence on adoption, regulatory strategy, and commercial priorities for bone pin stakeholders. In the Americas, health systems emphasize cost-effectiveness and outcome-based purchasing, driving manufacturers to present robust clinical data and predictable supply arrangements. Private and public providers in this region may diverge on procurement timelines and contracting preferences, prompting companies to adopt flexible engagement models to address both centralized group purchasing and localized procurement decision-making.
In Europe, Middle East & Africa, regulatory heterogeneity and variable reimbursement landscapes necessitate tailored entry strategies that blend clinical evidence with localized stakeholder education. Market access pathways can be complex, and partnerships with regional distributors or clinical champions often facilitate adoption. In Asia-Pacific, rapid modernization of healthcare infrastructure combined with increasing surgical volumes is accelerating demand for innovative fixation solutions, but local manufacturing capability and cost sensitivities influence competitive dynamics. Across all regions, clinical training, service-level commitments, and supply reliability remain pivotal factors guiding purchasing behavior and long-term adoption trajectories.
Competitive and corporate insights that characterize how legacy manufacturers, specialty innovators and strategic partnerships shape capability development and clinician preference
Competitive dynamics in the bone pin space are shaped by a mix of legacy device manufacturers, specialty orthopedic firms, and emerging innovators focused on biodegradable technologies and advanced alloys. Leading organizations invest in iterative device improvements, build surgical education programs to drive clinician preference, and expand downstream service capabilities such as case support and instrument sterilization logistics. Collaboration between device designers and clinical investigators has intensified, producing more rigorous post-market evidence and enabling clearer differentiation on safety and performance metrics.
Smaller entrants often concentrate on niche innovations-whether a novel polymer formulation or a proprietary surface treatment-that address a specific clinical pain point. Meanwhile, strategic partnerships and licensing arrangements are common as firms seek to balance internal development costs with faster time-to-clinic through co-development. Procurement teams evaluate these dynamics by weighing vendor stability, product breadth, and the availability of training and clinical support. Ultimately, companies that combine reliable manufacturing, clear clinical value, and strong clinician engagement tend to rise as preferred suppliers across diverse care settings.
Actionable recommendations for product, clinical, supply chain and commercial strategies that accelerate adoption and protect margins amid evolving policy and clinical expectations
To capitalize on current opportunities and mitigate emerging risks, industry leaders should adopt a multidimensional strategy that aligns product development, clinical evidence, and commercial operations. First, prioritize material differentiation by investing in comparative clinical studies that highlight the practical benefits and limitations of biodegradable metals and polymers versus traditional stainless steel and titanium counterparts. Second, refine product portfolios to offer clear positioning between smooth and threaded designs, accompanied by surgeon-focused training that demonstrates real-world procedural advantages.
Third, strengthen supply chain resilience by diversifying sourcing, exploring regional manufacturing options, and establishing contingency inventory practices with key hospital systems. Fourth, tailor market access approaches to regional procurement behaviors by combining direct engagement with hospitals, partnerships with local distributors, and selective use of online channels for lower-complexity products. Fifth, expand post-market support services and educational outreach to reinforce clinician confidence and to demonstrate commitment to long-term device performance. By synchronizing these initiatives, leaders can improve adoption pathways, protect margins in the face of trade policy shifts, and build durable relationships with surgical stakeholders.
A blended research methodology combining primary clinician and procurement engagement with secondary clinical, regulatory and product intelligence to ensure robust validated conclusions
The research synthesis draws on a blended methodology combining primary qualitative engagement with clinicians, procurement professionals and device developers, and secondary analysis of clinical literature, regulatory filings, and product technical documents. Primary interviews were conducted with practicing orthopedic surgeons, dental surgeons who specialize in fixation procedures, hospital purchasing managers, and supply chain leaders to capture real-world adoption considerations and operational constraints. These conversations were supplemented by in-depth reviews of device labeling, published clinical studies, and regulatory guidance to validate performance assertions and to assess safety surveillance mechanisms.
Data triangulation was applied to reconcile insights from diverse sources, and thematic analysis identified recurring drivers such as material performance, ease of surgical use, and post-operative outcomes. Competitive landscaping integrated product specifications, distribution models, and public disclosures to map capability clusters across industry participants. Throughout, the methodology emphasized transparency in source attribution and iterative validation with clinical experts to ensure the conclusions reflect current practice patterns and actionable commercial intelligence rather than anecdotal impressions.
A concise conclusion synthesizing clinical, technological, regulatory and commercial forces that collectively determine adoption and long-term success in bone pin deployment
In sum, the bone pin ecosystem is evolving rapidly under the influence of clinical demand for improved outcomes, advances in material science, and shifting commercial imperatives. Innovation in biodegradable metals and polymers challenges traditional material choices, while product geometry and application-specific design drive clinical suitability across dental, external fixation, internal fixation, and spinal procedures. End users ranging from ambulatory centers and specialty clinics to private and public hospitals exert distinct procurement pressures that require differentiated sales and support approaches. Meanwhile, regional regulatory and reimbursement nuances shape go-to-market strategies and partnership models.
Given these dynamics, stakeholders who integrate rigorous clinical evidence with resilient supply chains and targeted commercial programs will be positioned to capture clinician preference and long-term utilization. Ongoing engagement with surgical communities, proactive regulatory planning, and deliberate investment in service-level support will further strengthen adoption prospects. The convergence of these elements underscores the need for focused execution across product design, clinical validation, and market access to deliver devices that meet both procedural demands and institutional thresholds for value.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction framing clinical needs, regulatory expectations, material innovation and supply dynamics that shape contemporary bone pin deployment
The contemporary bone pin landscape sits at the intersection of surgical necessity, materials science, and evolving care models. Clinicians consistently seek implants that deliver predictable fixation while minimizing complications, and this demand has driven a nuanced expansion of available materials and product designs. Meanwhile, regulatory and reimbursement pressures incentivize manufacturers to demonstrate clinical differentiation through comparative outcomes, device safety improvements, and clear value propositions for providers and payers. As a result, stakeholders across the value chain are recalibrating priorities to emphasize biocompatibility, ease of use in the operating theater, and downstream patient recovery metrics.
Transitioning from traditional stainless steel options to novel biodegradable constructs reflects a broader shift toward implants that mitigate long-term hardware complications and secondary procedures. Concurrently, the refinement of threaded and smooth pin formats has focused on surgical ergonomics and fixation predictability across anatomical sites. Supply chain resilience and manufacturing scalability remain focal points as providers demand consistent quality and timely availability. Taken together, these forces create a dynamic environment where clinical evidence, materials innovation, regulatory clarity, and commercial execution converge to define competitive advantage for industry participants.
How evolving clinical priorities, regulatory refinement, supply chain pressures and material breakthroughs are collectively redefining strategic priorities across the bone pin sector
The bone pin sector is undergoing transformative shifts prompted by changes in clinical practice, material engineering, and care delivery pathways. Surgeons are increasingly selective in implant choice, favoring devices that reduce secondary interventions and improve rehabilitation timelines. This clinical preference has elevated interest in biodegradable options and high-performance alloys, prompting manufacturers to accelerate development and to curate evidence that speaks directly to operative efficiency and patient-centric outcomes. In parallel, digital health technologies and improved imaging capabilities are refining preoperative planning and implant selection, enabling more precise fixation strategies and tailored device selection for complex anatomies.
Regulatory evolution is another critical vector of change. Authorities are refining guidance around post-market surveillance and comparative clinical assessment, which in turn raises the bar for demonstrating safety and long-term performance. Payors and hospital purchasing groups are responding by prioritizing devices that demonstrate total cost of care improvements rather than simple unit price reductions. Supply chain pressures and raw material availability have created incentives for regional manufacturing and strategic inventory management. Altogether, these shifts compel manufacturers to adopt integrated product development plans that align material science innovations, clinical evidence generation, and robust commercialization frameworks to remain competitive in a rapidly advancing clinical landscape.
Strategic responses to tariff-induced supply pressures that drive sourcing diversification, nearshoring considerations and procurement frameworks to protect surgical continuity
Tariff policy and trade measures can materially influence sourcing decisions, manufacturing footprints, and procurement strategies across the medical device ecosystem. Recent changes to United States tariff structures have reverberated through supply chains, prompting some manufacturers to reassess overseas production models and to explore nearshoring or dual-sourcing approaches. This recalibration affects not only raw material procurement but also the costs and logistics associated with finished device distribution. Hospitals and purchasing departments are consequently adjusting contract terms and inventory policies to mitigate potential disruptions and price variability.
In response, many organizations are increasing transparency across supplier relationships and investing in scenario planning to preserve surgical continuity. Device developers are evaluating potential redesigns that optimize material utilization and reduce dependency on tariff-exposed components. At the same time, procurement groups are enhancing their evaluation frameworks to consider total delivered cost, lead time certainty, and supplier risk profiles rather than focusing on per-unit list prices alone. These practices create a more resilient commercial environment but also require closer collaboration between clinical, regulatory, and supply chain teams to maintain device availability for critical procedures.
Key segmentation insights that illuminate how material science, device architecture, clinical application, end user dynamics and sales channels shape product differentiation
A nuanced understanding of segmentation is essential to navigate product development and commercialization for bone pins. Based on material, product portfolios include biodegradable options as well as traditional stainless steel and titanium constructs; the biodegradable category itself is differentiated into metal and polymer variants, where metal biodegradable pins commonly leverage magnesium alloys and polymer biodegradable pins utilize chemistries such as polyglycolic acid and polylactic acid. Each material pathway presents distinct clinical trade-offs in terms of degradation profiles, fixation strength, and imaging compatibility, and these characteristics influence surgeon preference and device positioning within treatment algorithms.
Based on product type, offerings typically distinguish between smooth pins and threaded pins, with each geometry delivering specific insertion dynamics and holding characteristics relevant to clinical scenarios. Based on application, bone pins are deployed across dental surgery, external fixation, internal fixation, and spinal surgery contexts, requiring tailored design considerations for anatomical constraints and biomechanical loads. Based on end user, adoption patterns differ among ambulatory centers, hospitals, orthopedic clinics, and specialty centers, with hospitals further segmented into private and public providers that operate under divergent procurement and budgetary regimes. Based on sales channel, distribution is achieved through direct sales, distributors, hospital purchasing departments, and online channels, and each route to market demands distinct commercial capabilities and support models. Integrating these segmentation layers enables more precise targeting of clinical evidence generation, pricing strategies, and post-market support to satisfy diverse stakeholder needs.
Comparative regional insights highlighting how procurement norms, regulatory environments and clinical adoption patterns vary across the Americas, Europe Middle East & Africa and Asia-Pacific
Regional dynamics exert a strong influence on adoption, regulatory strategy, and commercial priorities for bone pin stakeholders. In the Americas, health systems emphasize cost-effectiveness and outcome-based purchasing, driving manufacturers to present robust clinical data and predictable supply arrangements. Private and public providers in this region may diverge on procurement timelines and contracting preferences, prompting companies to adopt flexible engagement models to address both centralized group purchasing and localized procurement decision-making.
In Europe, Middle East & Africa, regulatory heterogeneity and variable reimbursement landscapes necessitate tailored entry strategies that blend clinical evidence with localized stakeholder education. Market access pathways can be complex, and partnerships with regional distributors or clinical champions often facilitate adoption. In Asia-Pacific, rapid modernization of healthcare infrastructure combined with increasing surgical volumes is accelerating demand for innovative fixation solutions, but local manufacturing capability and cost sensitivities influence competitive dynamics. Across all regions, clinical training, service-level commitments, and supply reliability remain pivotal factors guiding purchasing behavior and long-term adoption trajectories.
Competitive and corporate insights that characterize how legacy manufacturers, specialty innovators and strategic partnerships shape capability development and clinician preference
Competitive dynamics in the bone pin space are shaped by a mix of legacy device manufacturers, specialty orthopedic firms, and emerging innovators focused on biodegradable technologies and advanced alloys. Leading organizations invest in iterative device improvements, build surgical education programs to drive clinician preference, and expand downstream service capabilities such as case support and instrument sterilization logistics. Collaboration between device designers and clinical investigators has intensified, producing more rigorous post-market evidence and enabling clearer differentiation on safety and performance metrics.
Smaller entrants often concentrate on niche innovations-whether a novel polymer formulation or a proprietary surface treatment-that address a specific clinical pain point. Meanwhile, strategic partnerships and licensing arrangements are common as firms seek to balance internal development costs with faster time-to-clinic through co-development. Procurement teams evaluate these dynamics by weighing vendor stability, product breadth, and the availability of training and clinical support. Ultimately, companies that combine reliable manufacturing, clear clinical value, and strong clinician engagement tend to rise as preferred suppliers across diverse care settings.
Actionable recommendations for product, clinical, supply chain and commercial strategies that accelerate adoption and protect margins amid evolving policy and clinical expectations
To capitalize on current opportunities and mitigate emerging risks, industry leaders should adopt a multidimensional strategy that aligns product development, clinical evidence, and commercial operations. First, prioritize material differentiation by investing in comparative clinical studies that highlight the practical benefits and limitations of biodegradable metals and polymers versus traditional stainless steel and titanium counterparts. Second, refine product portfolios to offer clear positioning between smooth and threaded designs, accompanied by surgeon-focused training that demonstrates real-world procedural advantages.
Third, strengthen supply chain resilience by diversifying sourcing, exploring regional manufacturing options, and establishing contingency inventory practices with key hospital systems. Fourth, tailor market access approaches to regional procurement behaviors by combining direct engagement with hospitals, partnerships with local distributors, and selective use of online channels for lower-complexity products. Fifth, expand post-market support services and educational outreach to reinforce clinician confidence and to demonstrate commitment to long-term device performance. By synchronizing these initiatives, leaders can improve adoption pathways, protect margins in the face of trade policy shifts, and build durable relationships with surgical stakeholders.
A blended research methodology combining primary clinician and procurement engagement with secondary clinical, regulatory and product intelligence to ensure robust validated conclusions
The research synthesis draws on a blended methodology combining primary qualitative engagement with clinicians, procurement professionals and device developers, and secondary analysis of clinical literature, regulatory filings, and product technical documents. Primary interviews were conducted with practicing orthopedic surgeons, dental surgeons who specialize in fixation procedures, hospital purchasing managers, and supply chain leaders to capture real-world adoption considerations and operational constraints. These conversations were supplemented by in-depth reviews of device labeling, published clinical studies, and regulatory guidance to validate performance assertions and to assess safety surveillance mechanisms.
Data triangulation was applied to reconcile insights from diverse sources, and thematic analysis identified recurring drivers such as material performance, ease of surgical use, and post-operative outcomes. Competitive landscaping integrated product specifications, distribution models, and public disclosures to map capability clusters across industry participants. Throughout, the methodology emphasized transparency in source attribution and iterative validation with clinical experts to ensure the conclusions reflect current practice patterns and actionable commercial intelligence rather than anecdotal impressions.
A concise conclusion synthesizing clinical, technological, regulatory and commercial forces that collectively determine adoption and long-term success in bone pin deployment
In sum, the bone pin ecosystem is evolving rapidly under the influence of clinical demand for improved outcomes, advances in material science, and shifting commercial imperatives. Innovation in biodegradable metals and polymers challenges traditional material choices, while product geometry and application-specific design drive clinical suitability across dental, external fixation, internal fixation, and spinal procedures. End users ranging from ambulatory centers and specialty clinics to private and public hospitals exert distinct procurement pressures that require differentiated sales and support approaches. Meanwhile, regional regulatory and reimbursement nuances shape go-to-market strategies and partnership models.
Given these dynamics, stakeholders who integrate rigorous clinical evidence with resilient supply chains and targeted commercial programs will be positioned to capture clinician preference and long-term utilization. Ongoing engagement with surgical communities, proactive regulatory planning, and deliberate investment in service-level support will further strengthen adoption prospects. The convergence of these elements underscores the need for focused execution across product design, clinical validation, and market access to deliver devices that meet both procedural demands and institutional thresholds for value.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid adoption of bioabsorbable polymer bone pins in pediatric fracture care reducing the need for secondary removal procedures
- 5.2. Growth of 3D printed patient-specific bone pins enhancing anatomical fit and improving surgical outcomes in complex fractures
- 5.3. Development of antibiotic-coated titanium bone pins aimed at minimizing postoperative infections and improving recovery rates
- 5.4. Introduction of radiopaque composite bone pins to provide real-time imaging visibility during minimally invasive orthopedic procedures
- 5.5. Shift toward high-performance PEEK composite bone pins offering superior biocompatibility and mechanical strength in load-bearing applications
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Bone Pins Market, by Product Type
- 8.1. Smooth Pin
- 8.2. Threaded Pin
- 9. Bone Pins Market, by Material
- 9.1. Biodegradable
- 9.1.1. Metal
- 9.1.2. Polymer
- 9.1.2.1. Polyglycolic Acid
- 9.1.2.2. Polylactic Acid
- 9.2. Stainless Steel
- 9.3. Titanium
- 10. Bone Pins Market, by Application
- 10.1. Dental Surgery
- 10.2. External Fixation
- 10.3. Internal Fixation
- 10.4. Spinal Surgery
- 11. Bone Pins Market, by End User
- 11.1. Ambulatory Centers
- 11.2. Hospitals
- 11.2.1. Private
- 11.2.2. Public
- 11.3. Orthopedic Clinics
- 11.4. Specialty Centers
- 12. Bone Pins Market, by Sales Channel
- 12.1. Direct Sales
- 12.2. Distributors
- 12.3. Hospital Purchasing Departments
- 12.4. Online Channels
- 13. Bone Pins Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Bone Pins Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Bone Pins Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Acumed by Colson Medical, LLC
- 16.3.2. Arthrex, Inc.
- 16.3.3. Assure Enterprises
- 16.3.4. CONMED Corporation
- 16.3.5. Gebr. Brasseler GmbH & Co. KG
- 16.3.6. GerVetUSA
- 16.3.7. GPC Medical Ltd.
- 16.3.8. GWS Surgicals LLP.
- 16.3.9. HAROLDMEDI LLC
- 16.3.10. HEMC Ortho
- 16.3.11. Innomed, Inc.
- 16.3.12. Integra LifeSciences Holdings Corporation
- 16.3.13. Johnson & Johnson
- 16.3.14. Kaushik Orthopaedic Pvt. Ltd.
- 16.3.15. Medline Industries, LP.
- 16.3.16. Medtronic plc
- 16.3.17. MicroPort Scientific Corporation
- 16.3.18. Nebula Surgical Pvt. Ltd.
- 16.3.19. Orthofix Medical Inc.
- 16.3.20. reens Surgicals Pvt. Ltd.
- 16.3.21. RTI Surgical Holdings, Inc.
- 16.3.22. Shagun Cares Inc.
- 16.3.23. Sharma Orthopedic (India) Private Limited
- 16.3.24. Sky Surgicals
- 16.3.25. Smit Medimed Pvt. Ltd.
- 16.3.26. Smith & Nephew plc
- 16.3.27. Stryker Corporation
- 16.3.28. Surgical Holdings
- 16.3.29. Zimmer Biomet Holdings, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
